Modified classification for adenocarcinoma of the gastro-oesophageal junction

被引:4
|
作者
Shearer, Christopher J.
Going, James J.
Neilson, Lisa J.
Stuart, Robert C.
机构
[1] Univ Glasgow, Glasgow Royal Infirm, Dept Surg, Glasgow G31 2ER, Lanark, Scotland
[2] Univ Glasgow, Glasgow Royal Infirm, Dept Pathol, Glasgow G31 2ER, Lanark, Scotland
关键词
adenocarcinoma; cytokeratin; gastro-oesophageal junction;
D O I
10.1111/j.1445-2197.2007.04147.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Incidence of the gastro-oesophageal junction adenocarcinoma is increasing. Siewert's classification subdivides junctional adenocarcinomas anatomically. Cytokeratin (CK) 7 and 20 immunophenotypes differentiate Barrett's intestinal metaplasia (IM) from gastric IM. Comparing CK immunostaining with Siewert's classification may establish tumour origin and influence surgical choice. Methods: In this experimental study, 57 patients with gastro-oesophageal junction adenocarcinoma were subdivided endoscopically into 15 type 1, 26 type 2 and 16 type 3 adenocarcinomas. Representative biopsies were immunostained for CK7 and CK20. Results: Intestinal metaplasia was associated with type 1 adenocarcinoma in 12 of 15 patients, 80%; with type 2 in 13 of 26 patients, 50% and type 3 in 6 of 16 patients, 37.5%. All type 1 patients showed Barrett's CK7/CK20 phenotype within IM; type 2 a mixture: 69% (n = 9) Barrett's CK7/CK20 and 31% (n = 4) gastric CK7/CK20 whereas type 3 patients had a gastric CK7/CK20 pattern in 83% (n = 5). Immunostaining within the adenocarcinoma was variable. Conclusion: Siewert's type 1 adenocarcinomas express Barrett's CK7/CK20 pattern, type 3 a gastric CK7/CK20 pattern and type 2 tumours a mixture of Barrett's and gastric CK7/CK20 patterns within associated IM. CK immunostaining may refine Siewert's classification into oesophageal type 1 or gastric type 2 adenocarcinoma with IM.
引用
收藏
页码:544 / 549
页数:6
相关论文
共 50 条
  • [1] Aetiology and classification of adenocarcinoma of the gastro-oesophageal junction/cardia
    McColl, Kenneth E. L.
    Going, James J.
    [J]. GUT, 2010, 59 (03) : 282 - 284
  • [2] CROSS versus modified MAGIC or FLOT in oesophageal and gastro-oesophageal junction adenocarcinoma
    van Rossum, Peter S. N.
    van Laarhoven, Hanneke W. M.
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (11): : 959 - 960
  • [3] THE RELEVANCE OF THE SIEWERT CLASSIFICATION IN THE ERA OF MULTIMODAL THERAPY FOR ADENOCARCINOMA OF THE GASTRO-OESOPHAGEAL JUNCTION
    Noble, F.
    Bailey, I. S.
    Kelly, J. J.
    Byrne, J. P.
    Underwood, T. J.
    [J]. GUT, 2012, 61 : A313 - A313
  • [4] The Relevance of the Siewert Classification in the Era of Multimodal Therapy for Adenocarcinoma of the Gastro-Oesophageal Junction
    Curtis, Nathan J.
    Noble, Fergus
    Bailey, Ian S.
    Kelly, Jamie J.
    Byrne, James P.
    Underwood, Timothy J.
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2014, 109 (03) : 202 - 207
  • [5] Adenocarcinoma of the gastro-oesophageal junction with a synchronous carcinoid of the duodenum
    McCabe, HL
    [J]. POSTGRADUATE MEDICAL JOURNAL, 2001, 77 (906) : 255 - 256
  • [6] The Role of Nutritional Status in Oesophageal and Gastro-Oesophageal Junction Adenocarcinoma.
    Douglas, R. V.
    Singh, U.
    Sutton, E.
    Williams, A.
    McCaughey, S.
    Kennedy, R.
    Turkington, R. C.
    [J]. BRITISH JOURNAL OF SURGERY, 2019, 106 : 150 - 150
  • [7] Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma
    Connie Kang
    [J]. Targeted Oncology, 2023, 18 (6) : 981 - 989
  • [8] Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma
    Young, Kate
    Smyth, Elizabeth
    Chau, Ian
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2015, 8 (06): : 373 - 383
  • [9] Pattern of recurrence after surgery in adenocarcinoma of the gastro-oesophageal junction
    de Manzoni, G
    Pedrazzani, C
    Pasini, F
    Durante, E
    Gabbani, M
    Grandinetti, A
    Guglielmi, A
    Griso, C
    Cordiano, C
    [J]. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2003, 29 (06): : 506 - 510
  • [10] Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma
    Kang, Connie
    [J]. TARGETED ONCOLOGY, 2023, 18 (06) : 981 - 989